Skip to content

XOMA Corporation XOMA Non-cash interest expense

Non-cash interest expense at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
Innoviva, Inc. logo
Innoviva, Inc.INVA
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$746.04M+159%
Enterprise value$785.17M+152%
P/E22.1×
P/S15.4×+8.7×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Reported directly by XOMA Corporation in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's non-cash interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's non-cash interest expense?
XOMA Corporation (XOMA) reported non-cash interest expense of $332K in Q1 2026.
How has XOMA Corporation's non-cash interest expense changed year-over-year?
XOMA Corporation's non-cash interest expense decreased by 22.2% year-over-year, from $427K to $332K.
What is the long-term trend for XOMA Corporation's non-cash interest expense?
Over 2 years (2023 to 2025), XOMA Corporation's non-cash interest expense has grown at a 538.2% compound annual growth rate (CAGR), from $34K to $1.39M.